DOCSLIB.ORG

Pain Management in Sickle Cell Anemia

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pain Management in Sickle Cell Anemia 7/10/2019 #FSHP2019 Disclosure #FSHP2019 I do not have (nor does any immediate family member Pain Management in have): – a vested interest in or affiliation with any corporate Sickle Cell Anemia organization offering financial support or grant monies for this continuing education activity – any affiliation with an organization whose philosophy could potentially bias my presentation Joseph Cammilleri, Pharm.D, BCACP, CPE Ambulatory Care Clinical Pharmacist UF Health Jacksonville 12 Objectives #FSHP2019 #FSHP2019 • Describe the types and characteristics of pain associated with sickle-cell disease • Discuss treatment of pain in patients with sickle-cell disease • Review clinical pearls in the management of acute versus chronic pain Saunthararajah, Y., et al. Sickle Cell Disease: Clinical Features and Management. Hoffman: Hematology 2012. 34 Pathophysiology #FSHP2019 Pathophysiology #FSHP2019 Hb A Hb S Ischemia/Reperfusion Vascular Occlusion Solubility Soluble Insoluble O2 Systemic Inflammation O2 Exposed hydrophobic Deoxygenation Maintains Shape Endothelial pockets Dysfunction Healthy ‘Sticky,’ rigid RBC Effects Lifespan ~120 days Lifespan 10-20 days Hemolysis Anemia, heme release CDC. Sickle Cell Disease. August 2017. Nat Rev Nephrol. 2015 Mar; 11(3): 161–171. Pharmacotherapy: A Pathophys Approach. 9th ed; 2014. Image: practicalpainmanagement.com/resources 56 1 7/10/2019 Genetics #FSHP2019 Prevalence #FSHP2019 • Sickle Cell Disease • 1:396 AA Births • 1:36,000 H Births • Sickle Cell Anemia • Hb SS • Hb S-β thal • Hb SC AA= African American H= Hispanic Saunthararajah, Y., et al. Sickle Cell Disease: Clinical Features and Management. Hoffman: Hematology 2012. F Piel et al Sickle Cell Disease N Engl J Med 2017; 376:1561-1573 78 Diagnosis #FSHP2019 Complications #FSHP2019 • CBC Acute Chronic • Peripheral smear VOCs Retinopathy Infection (IPD) Nephropathy Pulmonary Disease • Solubility test Priapism Osteonecrosis Acute Chest Syndrome Delayed growth • Hb electrophoresis Stroke Stasis Ulcers Splenic Sequestration Increased risk of Infection VOC = vaso-occlusive crisis; Peds in Review. 2012; 33 (5): 195. Lancet. 2017; 390:311-23. Saunthararajah, Y., et al. Sickle Cell Disease: Clinical Features and Management. Hoffman: Hematology 2012. IPD = Invasive pneumococcal disease Pharmacotherapy: A Pathophys Approach. 9th ed; 2014. 910 Infection #FSHP2019 Fever #FSHP2019 • Abnormal immune function • Medical emergency • Immunizations • IV antibiotics • Temp >101.3 • Penicillin prophylaxis • Penicillin VK 125mg once daily (3yo) • Penicillin VK 250mg BID Peds in Review. 2012; 33 (5): 195. Peds in Review. 2012; 33 (5): 195. Lancet. 2017; 390:311-23. Lancet. 2017; 390:311-23. Pharmacotherapy: A Pathophys Approach. 9th ed; 2014. Pharmacotherapy: A Pathophys Approach. 9th ed; 2014. 11 12 2 7/10/2019 Dactylitis #FSHP2019 Splenic Sequestration #FSHP2019 • Hand-foot syndrome • Life-threatening • Treatment • Fluids/blood transfusion • Splenectomy • Inflammation • Primarily in infants • Pain medication • Symptoms • Engorgement of the spleen • Hypovolemia • Decrease hemoglobin Peds in Review. 2012; 33 (5): 195. Peds in Review. 2012; 33 (5): 195. Lancet. 2017; 390:311-23. Lancet. 2017; 390:311-23. Pharmacotherapy: A Pathophys Approach. 9th ed; 2014. Pharmacotherapy: A Pathophys Approach. 9th ed; 2014. 13 14 Acute Chest Syndrome #FSHP2019 Priapism #FSHP2019 • 2nd most common reason • Treatment • Painful Erection for admission • Blood transfusion/fluids • Oxygen • Antibiotics • Common • Sign/Symptoms • 90% by 20yo • New radiodensity • Fever • Treatment • Respiratory distress • Supported therapy (sitz bath/pain medication) • Pain • Aspiration of blood Peds in Review. 2012; 33 (5): 195. Peds in Review. 2012; 33 (5): 195. Lancet. 2017; 390:311-23. Lancet. 2017; 390:311-23. Pharmacotherapy: A Pathophys Approach. 9th ed; 2014. Pharmacotherapy: A Pathophys Approach. 9th ed; 2014. 15 16 Kidney Disease #FSHP2019 Neurologic Complications #FSHP2019 • Gross hematuria • Strokes (11%-20%) • Papillary necrosis • Treatment - Oxygen and blood transfusion • Primary Prevention – Blood transfusion • Nephrotic syndrome • Secondary Prevention – Blood transfusion • Renal infarction Up to 18% CKD • Hyposthenuria • Headache • Pyelonephritis • Renal medullary carcinoma • Seizures Peds in Review. 2012; 33 (5): 195. Peds in Review. 2012; 33 (5): 195. Lancet. 2017; 390:311-23. Lancet. 2017; 390:311-23. Pharmacotherapy: A Pathophys Approach. 9th ed; 2014. Pharmacotherapy: A Pathophys Approach. 9th ed; 2014. 17 18 3 7/10/2019 Iron Overload #FSHP2019 Hydroxyurea #FSHP2019 • Cause – Blood transfusions • Class: ribonucleotide reductase inhibitor • Mechanism: stimulates production of • Consequences – Organ damage Hemoglobin F (HbF) • Stimulate erythropoiesis • NO release and synthesis • Assessment - MRI, Biopsy, Ferritin level • Antioxidant effects • Uses: • Treatment – Chelating agents • Prolong duration between SCD relapses • Delay organ damage HbF = fetal hemoglobin Peds in Review. 2012; 33 (5): 195. Peds in Review. 2012; 33 (5): 195. Lancet. 2017; 390:311-23. SCD = sickle cell disease NHLBI. SCD Guidelines. 2014. Pharmacotherapy: A Pathophys Approach. 9th ed; 2014. NO = nitric oxide Pharmacotherapy: A Pathophys Approach. 9th ed; 2014. 19 20 #FSHP2019 #FSHP2019 Multicenter Study of Hydroxyurea Multicenter Study of Hydroxyurea Charache, et al. (1995) Charache, et al. (1995) Objective Occurrence of Acute Pain Crises • Determine efficacy of hydroxyurea in reducing frequency of SCD crises • 44% reduction of acute crises per year (2.5 vs 4.5 crises; p<0.001) • 58% reduction in crises requiring hospitalization (1 vs 2.4 crises; p<0.001) Design • Randomized (1:1), double-blind, placebo-controlled Other Outcomes • Planned 24-month follow-up • Prolonged time to first crisis (3 vs 1.5 months; p=0.01) Inclusion (n=299) • Decreased incidence of acute chest syndrome (25 vs 51 patients; • Adults >18 years with ≥ 3 crises in the year prior to enrollment p<0.001) • Excluded HbSβ0, HbSβ+ • Interruption for myelosuppression was more common with hydroxyurea (14 vs 6 patients) SCD = Sickle cell disease 0 + NEJM. 1995. 20 (322):1317-22. HbSβ / HbSβ = β -thalassemia major/minor NEJM. 1995. 20 (322):1317-22. 21 22 Hydroxyurea in Pediatrics #FSHP2019 Hydroxyurea: Indications #FSHP2019 Acute or recurrent VOC complications Ferster, et al. (1996) Wang, et al. (2011; BABY HUG) • Single-blind, cross-over in • Randomized trial in children <18 children (N=25) with ≥ 3 months (N=193) crises per year Evidence of Organ Dysfunction • Primary Outcome: incidence of • Primary Outcomes splenic sequestration • Decreased hospitalization (6 • Thornburg et al (2012) vs 19 patients; p=0.0016) • 52% reduction in pain crises • Decreased hospital stay (5.3 15 mg/kg/day starting dose, titrated to mild toxicity (p<0.001) vs 15.2 days; p=0.0027) • 81% reduction in dactylitis • Did not report ADEs (p<0.001) • 28% reduction in hospitalization Limitations: Dose-related toxicity | Adherence requirements | Inadequate response Blood. 1996; 88 (6): 1960-4. NHLBI. SCD Guidelines. 2014. Lancet. 2011;377(9778):1663-72. Hematology. 2009; 62-9. Blood. 2012; 120(22):4304-10. VOC = vaso-occlusive crisis Ann Int Med. 2008; 148 (12): 939-55. 23 24 4 7/10/2019 Pain #FSHP2019 Acute Pain #FSHP2019 • IV Opioids • Cardinal feature • Precipitating factors: • Scheduled doses provide superior control • Vaso-occlusive crisis • Physical stress Udezue, et al. (2007) - RTC analgesics vs demand doses increased discharge at • Infection 72 hours (83% vs 71%; p<0.05) • Dehydration • Hypoxia • PCA • Acidosis • Benefits over scheduled infusion • Cold Van Beers, et al. (2007) - Decreased cumulative morphine consumption vs standard care at 3 days (p=0.018) • Swimming for •Non-significant reduction in pain scores (4.9 vs 5.3; p=0.09) prolonged periods PCA – Patient controlled analgesia RTC = round the clock NHLBI. SCD Guidelines. 2014. W Afr J Med. 2007; 26(3): 179-82 Saunthararajah, Y., et al. Sickle Cell Disease: Clinical Features and Management. Hoffman: Hematology 2012. RCT = randomized controlled trial Am J Hematol. 2007; 82:955-60. 25 26 Acute Pain #FSHP2019 Chronic Pain #FSHP2019 • Ketamine • MSH (1995) • NMDA antagonist • Pain medication required 40% of the time, up to 80% • Low dose infusion immediately following VOC • PiSCES (2005) • Adults reported SCD- related pain 55% of the time Image: http://drsunderman.com/dehydration-joint-pain/ Pain MME NHLBI. SCD Guidelines. 2014. NEJM. 1995. 20 (322):1317-22. J Pain Palliative Care Pharmacotherapy. 2018 Mar;32(1):20-2 Health Qual Life Outcomes. 2005; 3 (50). 27 28 Chronic Pain #FSHP2019 Methadone #FSHP2019 • Identifiable • Synthetic opioid • Vertebral fractures • µ agonist • Avascular necrosis • NMDA receptor antagonist • Osteoarthritis • Skin ulcers • Fast onset and long duration of action • Treatment • Opioids • Variable half-life • Adjunctive agents Saunthararajah, Y., et al. Sickle Cell Disease: Clinical Features and Management. Hoffman: Hematology 2012. Dolophine (methadone) package insert. Columbus, OH: Roxane Laboratories, Inc; Accessed April 2019. 29 30 5 7/10/2019 Metabolism #FSHP2019 Methadone Dangers #FSHP2019 • Hepatic – CYP450 • Drug interactions • CYP3A4 • CYP2B6 • • CYP2C19 QTc prolongation • Inactive metabolites • Inappropriate dosage/titration Dolophine (methadone) package insert. Columbus, OH: Roxane Laboratories, Inc; Accessed April 2019. Dolophine (methadone) package insert. Columbus, OH: Roxane Laboratories, Inc; Accessed April 2019. 31 32 Drug Interaction #FSHP2019 Enzyme Inhibitors/Inducers#FSHP2019
Load more

Recommended publications
  • Update on the Management of Pain, Agitation, and Delirium in the ICU
    Update on the Management of Pain, Agitation, and Delirium in the ICU Kevin E. Anger, Pharm.D., BCPS Gilles Fraser, Pharm.D., MCCM Paul M. Szumita, Pharm.D., BCCCP, Manager Investigational Drug Clinical Pharmacist in Critical BCPS, FCCM Service Brigham and Women’s Care Clinical Pharmacy Practice Manager Hospital Maine Medical Center Brigham and Women’s Hospital Boston, Massachusetts Portland, Maine Boston, Massachusetts Disclosures • Faculty have nothing to disclose. Objectives • Describe recent literature on management of pain, agitation, and delirium (PAD) in the intensive care unit (ICU). • Apply key concepts in the selection of sedatives, analgesics, and antipsychotic agents in critically ill patients. • Recommend methods to overcome key barriers to optimizing pain, sedation, and delirium pharmacotherapy in critically ill patients. Case-Based Approach to Pain Management in the ICU Kevin E. Anger, Pharm.D., BCPS Manager Investigational Drug Service Brigham and Women’s Hospital Boston, Massachusetts Time for a Poll How to vote via the web or text messaging From any browser From a text message Pollev.com/ashp 22333 152964 How to vote via text message How to vote via the web Question #1 DT is a 70 yo male w/ COPD, S/P XRT for NSC lung CA, now admitted to the medical ICU for respiratory failure secondary to pneumonia meeting ARDS criteria. Significant home medications include oxycodone sustained release 40mg TID, oxycodone 10- 20mg Q4hrs PRN pain, Advair 500/50mcg BID, ASA 81mg QD, and albuterol neb Q4hrs PRN. DT is intubated is currently
    [Show full text]
  • Pharmacists' Roles on the Pain Management Team, Fall 2014
    Fall 2014, Volume 8, Issue 2 Canadian Pharmacy > Research > Health Policy > Practice > Better Health Pharmacists’ Roles on the Pain Management Team harmacists are an important resource for managing pain in their patients, in order to both optimize treatment and Pprevent the unintended consequences of potent analgesics. While the role of pharmacists in pain management was first addressed inthe Translator Summer 2012 edition1, this rapidly evolving area of pharmacy practice has generated a number of innovative models that highlight the unique role of the pharmacist. As Canadian pharmacists embrace expanded scopes of practice, there is an opportunity to specifically leverage their services to assist patients in managing their pain. This issue of the Translator highlights four different approaches to enhanced involvement of pharmacists in the management of chronic pain: n Pharmacist-led management of chronic pain: a randomized controlled exploratory trial from the UK n A pharmacist-initiated intervention trial in osteoarthritis n A pharmacist-led pain consultation for patients with concomitant substance use disorders n The impact of pharmacists in translating evidence to patients with low back pain 1 The Translator, Summer 2012, 6:3 Pharmacist-led management of chronic pain in primary care: results from a randomized controlled exploratory trial Bruhn H, Bond CM, Elliott AM, et al. Pharmacist-led management of chronic pain in primary care; results from a randomized controlled exploratory trial. BMJ Open 2013;3:e002361. Issue: In the UK, an estimated 80% of medication review of each patient’s medical chronic pain sufferers still report pain after Pharmacist prescribing and records, followed by a face-to-face consul- four years of follow-up.1 Most patients refer reviewing pain medication may tation.
    [Show full text]
  • Pain Management in People Who Have OUD; Acute Vs. Chronic Pain
    Pain Management in People Who Have OUD; Acute vs. Chronic Pain Developer: Stephen A. Wyatt, DO Medical Director, Addiction Medicine Carolinas HealthCare System Reviewer/Editor: Miriam Komaromy, MD, The ECHO Institute™ This project is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) under contract number HHSH250201600015C. This information or content and conclusions are those of the author and should not be construed as the official position or policy of, nor should any endorsements be inferred by HRSA, HHS or the U.S. Government. Disclosures Stephen Wyatt has nothing to disclose Objectives • Understand the complexities of treating acute and chronic pain in patients with opioid use disorder (OUD). • Understand the various approaches to treating the OUD patient on an agonist medication for acute or chronic pain. • Understand how acute and chronic pain can be treated when the OUD patient is on an antagonist medication. Speaker Notes: The general Outline of the module is to first address the difficulties surrounding treating pain in the opioid dependent patient. Then to address the ways that patients with pain can be approached on either an agonist of antagonist opioid use disorder treatment. Pain and Substance Use Disorder • Potential for mutual mistrust: – Provider • drug seeking • dependency/intolerance • fear – Patient • lack of empathy • avoidance • fear Speaker Notes: It is the provider that needs to be well educated and skillful in working with this population. Through a better understanding of opioid use disorders as a disease, the prejudice surrounding the encounter with the patient may be reduced.
    [Show full text]
  • Perioperative Pain Management for the Chronic Pain Patient with Long-Term Opioid Use
    1.5 ANCC Contact Hours Perioperative Pain Management for the Chronic Pain Patient With Long-Term Opioid Use Carina Jackman In the United States nearly one in four patients present- patterns of preoperative opioid use. Approximately one ing for surgery reports current opioid use. Many of these in four patients undergoing surgery in the study re- patients suffer from chronic pain disorders and opioid ported preoperative opioid use (23.1% of the 34,186-pa- tolerance or dependence. Opioid tolerance and preexisting tient study population). Opioid use was most common chronic pain disorders present unique challenges in regard in patients undergoing orthopaedic spinal surgery to postoperative pain management. These patients benefi t (65%). This was followed by neurosurgical spinal sur- geries (55.1%). Hydrocodone bitartrate was the most from providers who are not only familiar with multimodal prevalent medication. Tramadol and oxycodone hydro- pain management and skilled in the assessment of acute pain, chloride were also common ( Hilliard et al., 2018 ). but also empathetic to their specifi c struggles. Chronic pain Given this signifi cant population of surgical patients patients often face stigmas surrounding their opioid use, with established opioid use, it is imperative for both and this may lead to underestimation and undertreatment nurses and all other providers to gain an understanding of their pain. This article aims to review the challenges of the complex challenges chronic pain patients intro- presented by these complex patients and provide strate- duce to the postoperative setting. gies for treating acute postoperative pain in opioid-tolerant patients. Defi nitions Common pain terminology as defined by the Chronic Pain and Long-Term International Association for the Study of Pain, a joint Opioid Use consensus statement by the American Society of Addiction Medicine, the American Academy of Pain The burden of chronic pain in the United States is stag- Medicine and the American Pain Society (2001 ), and the gering.
    [Show full text]
  • Menu of Pain Management Clinic Regulation
    Menu of Pain Management Clinic Regulation The United States is in the midst of an unprecedented epidemic of prescription drug overdose deaths.1 More than 38,000 people died of drug overdoses in 2010, and most of these deaths (22,134) were caused by overdoses involving prescription drugs.2 Three-quarters of prescription drug overdose deaths in 2010 (16,651) involved a prescription opioid pain reliever (OPR), which is a drug derived from the opium poppy or synthetic versions of it such as oxycodone, hydrocodone, or methadone.3 The prescription drug overdose epidemic has not affected all states equally, and overdose death rates vary widely between states. States have the primary responsibility to regulate and enforce prescription drug practice. Although state laws are commonly used to prevent injuries and their benefits have been demonstrated for a variety of injury types,4 there is little information on the effectiveness of state statutes and regulations designed to prevent prescription drug abuse and diversion. This menu is a first step in assessing pain management clinic laws by creating an inventory of state legal strategies in this domain. Introduction One type of law aimed at preventing inappropriate prescribing is regulation of pain management clinics, often called “pill mills” when they are sources of large quantities of prescriptions. Pill mills have become an increasing problem in the prescription drug epidemic, and laws have been enacted to prevent these facilities from prescribing controlled substances inappropriately. A law was included in this resource as a pain management clinic regulation if it requires state oversight and contains other requirements concerning ownership and operation of pain management clinics, facilities, or practice locations.
    [Show full text]
  • Palliative Care Symptom Guide
    July 2019 UPMC PALLIATIVE AND SUPPORTIVE INSTITUTE Palliative Care Symptom Guide Table of Contents: Pain Management ……………………………………………………………………………………………………………………….. Assessment …………………………………………………………………………………………………………………………… 1 Adjuvant and Non-Opioid Agents for Pain ……………………………………………………………………………………….... 2 Principles of Opioid Therapy ……………………………………………………………………………………………….….…. 3-4 Select Opioid Products ……………………………………………………………………………………………………………… 5 Opioid Equianalgesic Equivalencies ………………………………………………………………………...…………………..… 6 Patient Controlled Analgesia (PCA) ……………………………………………………………………………………………….. 7 Opioid Induced Constipation ……………………………………………………………………………………………………… 8-9 Prescribing Outpatient Naloxone ………………………………………………………………………………………………… 10 Interventional Pain Management …………………………………………………………………………………………………. 11 Medical Cannabinoids ……………………………………………………………………………………………………………… 12 Dyspnea ………………………………………………………………………………………………………………………………… Assessment ………………………………………………………………………………………………………………………… 13 Treatment …………………………………………………………………………………………………………………………… 14 Nausea and Vomiting Treatment ……………………………………………………………………………………………..……… 15 Delirium …………………………………………………………………………………………………………………………………. 16 Diagnostic Criteria ……………………………………………………………………………….……………………….………... 17 Treatment ………………………………………………………………………………..…………………………………………. 18 Depression and Anxiety Treatment ……………………………………………………..…………..…………………………….…. 19 Oral Secretions ……………………………………………………..…………………………………………………………………. 20 Spirituality Pearls ……………………………………………………..………………………………………………………………. 21 Palliative
    [Show full text]
  • Veterinary Anesthesia and Pain Management Secrets / Edited by Stephen A
    Publisher: HANLEY & BELFUS, INC. Medical Publishers 210 South 13th Street Philadelphia, PA 19107 (215) 546-7293; 800-962-1892 FAX (215) 790-9330 Web site: http://www.hanleyandbelfus.com Note to the reader Although the information in this book has been carefully reviewed for cor­ rectness of dosage and indications, neither the authors nor the editor nor the publisher can accept any legal responsibility for any errors or omissions that may be made. Neither the publisher nor the editor makes any warranty, expressed or implied, with respect to the material contained herein. Before prescribing any drug. the reader must review the manu­ facturer's correct product information (package inserts) for accepted indications, absolute dosage recommendations. and other information pertinent to the safe and effective use of the product described. This is especially important when drugs are given in combination or as an adjunct to other forms of therapy Library of Congress Cataloging-in-Publication Data Veterinary anesthesia and pain management secrets / edited by Stephen A. Greene. p. em. - (The Secrets Series®) Includes bibliographical references (p.). ISBN 1-56053-442-7 (alk paper) I. Veterinary anesthesia-Examinations, questions. etc. 2. Pain in animals­ Treatment-Examinations, questions, etc. I. Greene, Stephen A., 1956-11. Series. SF914.V48 2002 636 089' 796'076--dc2 I 2001039966 VETERINARY ANESTHESIA AND PAIN MANAGEMENT SECRETS ISBN 1-56053-442-7 © 2002 by Hanley & Belfus, Inc. All rights reserved. No part of this book may be repro­ duced, reused, republished. or transmitted in any form, or stored in a database or retrieval system, without written permission of the publisher Last digit is the print number: 9 8 7 6 5 4 3 2 CONTRIBUTORS G.
    [Show full text]
  • Pain Management & Palliative Care
    Guidelines on Pain Management & Palliative Care A. Paez Borda (chair), F. Charnay-Sonnek, V. Fonteyne, E.G. Papaioannou © European Association of Urology 2013 TABLE OF CONTENTS PAGE 1. INTRODUCTION 6 1.1 The Guideline 6 1.2 Methodology 6 1.3 Publication history 6 1.4 Acknowledgements 6 1.5 Level of evidence and grade of guideline recommendations* 6 1.6 References 7 2. BACKGROUND 7 2.1 Definition of pain 7 2.2 Pain evaluation and measurement 7 2.2.1 Pain evaluation 7 2.2.2 Assessing pain intensity and quality of life (QoL) 8 2.3 References 9 3. CANCER PAIN MANAGEMENT (GENERAL) 10 3.1 Classification of cancer pain 10 3.2 General principles of cancer pain management 10 3.3 Non-pharmacological therapies 11 3.3.1 Surgery 11 3.3.2 Radionuclides 11 3.3.2.1 Clinical background 11 3.3.2.2 Radiopharmaceuticals 11 3.3.3 Radiotherapy for metastatic bone pain 13 3.3.3.1 Clinical background 13 3.3.3.2 Radiotherapy scheme 13 3.3.3.3 Spinal cord compression 13 3.3.3.4 Pathological fractures 14 3.3.3.5 Side effects 14 3.3.4 Psychological and adjunctive therapy 14 3.3.4.1 Psychological therapies 14 3.3.4.2 Adjunctive therapy 14 3.4 Pharmacotherapy 15 3.4.1 Chemotherapy 15 3.4.2 Bisphosphonates 15 3.4.2.1 Mechanisms of action 15 3.4.2.2 Effects and side effects 15 3.4.3 Denosumab 16 3.4.4 Systemic analgesic pharmacotherapy - the analgesic ladder 16 3.4.4.1 Non-opioid analgesics 17 3.4.4.2 Opioid analgesics 17 3.4.5 Treatment of neuropathic pain 21 3.4.5.1 Antidepressants 21 3.4.5.2 Anticonvulsant medication 21 3.4.5.3 Local analgesics 22 3.4.5.4 NMDA receptor antagonists 22 3.4.5.5 Other drug treatments 23 3.4.5.6 Invasive analgesic techniques 23 3.4.6 Breakthrough cancer pain 24 3.5 Quality of life (QoL) 25 3.6 Conclusions 26 3.7 References 26 4.
    [Show full text]
  • Managing Pain Anywhere
    Managing Pain – Anywhere! The Role of the Pharmacist Lee Kral, PharmD, BCPS The University of Iowa Center for Pain Medicine November 2012 Outline 1. Patient care settings 2. Barriers to pharmacist involvement 3. Establishing a practice 4. Qualifications, resources 5. Benefits/outcomes Where is the Pain? Outpatient clinics ER Hospital OR/PACU Inpatient units Discharge Do YOU do pain management in your practice? YES NO Pharmacist involvement in pain management Practice sites Hospital settings Emergency Department – acute pain 21% Outpatient clinics – chronic pain 45% 12% Inpatient units – acute and/or chronic pain 22% Critical care Palliative Care Community hospitals Oncology Federal hospitals Surgery Hospice Adult Medicine Other OR/PACU – acute pain Where do PPC pharmacists come from? Providers perceive need Pharmacy department initiative Sentinel events, safety issues Drug diversion/enforcement concerns Joint Commission mandates Gradual practice transition (fam med, hem-onc) Pain management practice model shift Which of the following is something that a PPC pharmacist might do? a. Prescribe opioids b. Order urine toxicology c. Obtain medication histories d. Write orders for post-op pain in the PACU e. All of the above What are the barriers? Pharmacist lack of knowledge, expertise Budgetary constraints Resistance from medical staff Providers unfamiliar with qualifications Ignorance of nursing, medical, pharmacy staff Unclear role of the pharmacist Previously established methods Lack of mentorship What are the qualifications? PGY-2 Pain and Palliative Care residency Certified Pain Educator (ASPE) ASHP PPC traineeship American Academy of Pain Management Certificate programs Experience and interest Juba KM. J Pharmacy Practice 2012; 00(0):1-4 What are the outcomes? Clinic setting1 Generated > $100,000 annual true revenue Saved health plans > $455,000 annually Reduce pain scores Managed maintenance monitoring Opioid refill clinic2 Reduced drug costs Reduced utilization of health care services Provider satisfaction Improved patient behavior 1.
    [Show full text]
  • Post- Operative Pain- Relief
    PPoosstt-- OOppeerraattiivvee PPaaiinn-- RReelliieeff • Pain is often the patient’s presenting symptom. It can provide useful clinical information and it is your responsibility to use this information to help the patient and alleviate suffering. • Manage pain wherever you see patients (emergency, operating room and on the ward) and anticipate their needs for pain management after surgery and discharge. • Do not unnecessarily delay the treatment of pain; for example, do not transport a patient without analgesia simply so that the next practitioner can appreciate how much pain the person is experiencing. • Pain management is our job. Pain Management and Techniques • Effective analgesia is an essential part of postoperative management. • Important injectable drugs for pain are the opiate analgesics. Nonsteroidal anti-inflammatory drugs (NSAIDs), such as diclofenac (1 mg/kg) and ibuprofen can also be given orally and rectally, as can paracetamol (15 mg/kg). • There are three situations where an opiate might be given: pre- operatively, intra-operatively, post-operatively. •• Opiate premedication is rarely indicated, although an injured patient in pain may have been given an opiate before coming to the operating room. • Opiates given pre- or intraoperatively have important effects in the postoperative period since there may be delayed recovery and respiratory depression, even necessitating mechanical ventilation. (continued to next page) PPoosstt-- OOppeerraattiivvee PPaaiinn-- RReelliieeff ((ccoonnttiiinnuueedd)) • Short acting opiate fentanyl is used intra-operatively to avoid this prolonged effect. • Naloxone antagonizes (reverses) all opiates, but its effect quickly wears off. • Commonly available inexpensive opiates are pethidine and morphine. • Morphine has about ten times the potency and a longer duration of action than pethidine.
    [Show full text]
  • Pain Management in Patients with Substance-Use Disorders
    Pain Management in Patients with Substance-Use Disorders By Valerie Prince, Pharm.D., FAPhA, BCPS Reviewed by Beth A. Sproule, Pharm.D.; Jeffrey T. Sherer, Pharm.D., MPH, BCPS; and Patricia H. Powell, Pharm.D., BCPS Learning Objectives regarding drug interactions with illicit substances or prescribed pain medications. Finally, there are issues 1. Construct a therapeutic plan to overcome barri- ers to effective pain management in a patient with related to the comorbidities of the patient with addic- addiction. tion (e.g., psychiatric disorders or physical concerns 2. Distinguish high-risk patients from low-risk patients related to the addiction) that should influence product regarding use of opioids to manage pain. selection. 3. Design a treatment plan for the management of acute pain in a patient with addiction. Epidemiology 4. Design a pharmacotherapy plan for a patient with Pain is the second most common cause of work- coexisting addiction and chronic noncancer pain. place absenteeism. The prevalence of chronic pain may 5. Design a pain management plan that encompasses be much higher among patients with substance use dis- recommended nonpharmacologic components for orders than among the general population. In the 2006 a patient with a history of substance abuse. National Survey on Drug Use and Health, past-year alco- hol addiction or abuse occurred in 10.3% of men and 5.1% of women. In the same survey, 12.3% of men and Introduction 6.3% of women were reported as having a substance-use Pain, which is one of the most common reasons disorder (abuse or addiction) during the past year.
    [Show full text]
  • Pain Terminology for Family Caregivers
    Information for Family Caregivers Pain Terminology for Family Caregivers Term Definition Comment/Importance to Caregiving Pain An unpleasant physical and • Understanding the pain helps you share emotional experience important information with healthcare associated with or described in providers that can help to guide your terms of actual or potential treatment plan tissue damage • “Pain is whatever the older adult says it is, occurring whenever he/she says it does” TYPES OF PAIN Term Definition Comment/Importance to Caregiving Acute Pain Pain that is usually temporary • Understanding the type of pain helps you and results from something share important information that can help to specific, such as a surgery, an guide the treatment plan injury, or an infection. • Ineffectively treated acute pain can turn into chronic pain Chronic Pain A painful experience that • Also called persistent pain continues for a prolonged • It is estimated up to 80% of individuals living period that may or may not be in nursing homes have chronic pain associated with a disease, • A variety of diagnosis contribute to chronic typically 3 months or longer. pain in this population, including: osteoarthritis, cancer, post-stroke pain, diabetic peripheral neuropathy, and others Musculoskeletal Pain of the muscles, joints, • This pain is relatively well localized and is Pain connective tissues and bones. typically worse on movement • This type of pain is often described as a dull, or ‘background’ aching pain, although the area may be tender to pressure Breakthrough Pain that increases above the • Associated with cancer pain Pain level of pain addressed by • Reported in 2 out of 3 people with continuous ongoing analgesics.
    [Show full text]